OBJECTIVES: Acromegalics have been reported to be at an increased risk of colorectal neoplasm. However, the magnitude of the risk is still controversial and the mechanism has not been fully investigated. In this study, we attempted to determine the magnitude of the association between acromegaly and colorectal lesions after taking into account age, gender, smoking status, and treatment status. In addition, we assessed the relationship between colorectal lesions and serum growth hormone (GH) levels in acromegalics. METHODS: We conducted a case-control study by using 19 consecutive untreated patients (male:female = 11:8) who were newly diagnosed with acromegaly between 1990 and 2000. All patients underwent colonoscopy and received a histological diagnosis of colorectal lesions. Prevalence of hyperplastic polyp, adenoma, and carcinoma were compared with the prevalence in 76 controls matched for gender, age, and smoking status. Serum GH levels were compared between acromegalic patients with and without each type of colorectal lesion. RESULTS: The prevalence of hyperplastic polyp, adenoma, and carcinoma were significantly higher in the acromegalic patients compared to the controls (p < 0.05, odds ratios; 8.3, 4.2, and 9.8, respectively). In acromegalics, the presence of hyperplastic polyps and carcinomas were significantly associated with higher serum GH levels after adjusting for the other lesions and age (p < 0.05). CONCLUSIONS: After controlling for age, gender, smoking status, and treatment status, acromegaly was associated with significantly higher prevalence of colorectal hyperplastic polyp, adenoma, and carcinoma. High serum GH levels may be associated with the presence of hyperplastic polyp and carcinoma.
OBJECTIVES: Acromegalics have been reported to be at an increased risk of colorectal neoplasm. However, the magnitude of the risk is still controversial and the mechanism has not been fully investigated. In this study, we attempted to determine the magnitude of the association between acromegaly and colorectal lesions after taking into account age, gender, smoking status, and treatment status. In addition, we assessed the relationship between colorectal lesions and serum growth hormone (GH) levels in acromegalics. METHODS: We conducted a case-control study by using 19 consecutive untreated patients (male:female = 11:8) who were newly diagnosed with acromegaly between 1990 and 2000. All patients underwent colonoscopy and received a histological diagnosis of colorectal lesions. Prevalence of hyperplastic polyp, adenoma, and carcinoma were compared with the prevalence in 76 controls matched for gender, age, and smoking status. Serum GH levels were compared between acromegalicpatients with and without each type of colorectal lesion. RESULTS: The prevalence of hyperplastic polyp, adenoma, and carcinoma were significantly higher in the acromegalicpatients compared to the controls (p < 0.05, odds ratios; 8.3, 4.2, and 9.8, respectively). In acromegalics, the presence of hyperplastic polyps and carcinomas were significantly associated with higher serum GH levels after adjusting for the other lesions and age (p < 0.05). CONCLUSIONS: After controlling for age, gender, smoking status, and treatment status, acromegaly was associated with significantly higher prevalence of colorectal hyperplastic polyp, adenoma, and carcinoma. High serum GH levels may be associated with the presence of hyperplastic polyp and carcinoma.
Authors: Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson Journal: J Clin Endocrinol Metab Date: 2015-04-03 Impact factor: 5.958
Authors: Margaret Zacharin; Anurag Bajpai; Chung Wo Chow; Anthony Catto-Smith; Constantine Stratakis; Michelle W Wong; Rodney Scott Journal: J Med Genet Date: 2011-02-28 Impact factor: 6.318
Authors: Karen J Wernli; Polly A Newcomb; Yinghui Wang; Karen W Makar; Mazyar Shadman; Victoria M Chia; Andrea Burnett-Hartman; Michelle A Wurscher; Yingye Zheng; Margaret T Mandelson Journal: Growth Horm IGF Res Date: 2010-05-26 Impact factor: 2.372
Authors: M Parolin; F Dassie; L Russo; S Mazzocut; M Ferrata; E De Carlo; R Mioni; F Fallo; R Vettor; C Martini; P Maffei Journal: Pituitary Date: 2018-02 Impact factor: 4.107
Authors: C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio Journal: J Endocrinol Invest Date: 2009-04-29 Impact factor: 4.256
Authors: Robert E Carroll; Robert A Goodlad; Aleksandra J Poole; Angela L Tyner; R Brooks Robey; Steven M Swanson; Terry G Unterman Journal: Growth Horm IGF Res Date: 2009-04-29 Impact factor: 2.372